|Videos|October 3, 2019

Engaging Dentists and Orthopedic Surgeons in Stewardship

Debra Goff, PharmD, discusses why it is critical to engage dentists and orthopedic surgeons in antimicrobial stewardship activities.

Interview transcript: (modified slightly for readability)

Contagion®: Why is it important to engage private practice dentists and orthopedic surgeons in stewardship?

Goff: We need to [engage private practice dentists and orthopedic surgeons in stewardship] to avoid patients being stuck in the middle of opposing antibiotic prophylaxis recommendations. The orthopedic surgeons, once they do a hip or knee replacement, will often tell their patients, “every time you go to the dentist for a cleaning or any work, you need to take antibiotic prophylaxis,” and some will even tell them for life.

The American Dental Association guidelines clearly state antibiotic prophylaxis is not necessary for the majority of patients, so, the patient is stuck in the middle saying “which doctor am I supposed to listen to?” — and that is never appropriate. And so, for the same reasons we do stewardship in the hospital—those principles apply to dental stewardship. It's for our patients.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.